Price movement over the last 24 hours
Agnico Eagle Mines Ltd vs ClearPoint Neuro Inc — how do they compare? Agnico Eagle Mines Ltd trades at $144.77 (market cap $75.10B), while ClearPoint Neuro Inc trades at $17.39 (market cap $524.82M). The key difference: Agnico Eagle Mines Ltd is far larger — about 143.1× ClearPoint Neuro Inc's market cap, and Agnico Eagle Mines Ltd pays a 1.2% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| AEM | CLPT | |
|---|---|---|
Market Cap | $75.10B | $524.82M |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $29.60 |
52-Week Low | $116.14 | $8.66 |
Enterprise Value | $72.30B | $552.81M |
Dividend Yield | 1.2% | — |
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $150.33, down 2.29% amid a bearish technical signal but maintains strong fundamentals with a 14.59 P/E ratio and 39.46% net margin. Recent quarterly earnings consistently beat estimates, including Q1 2026 EPS of $3.40 versus $3.19 expected. Revenue grew to $11.91B in 2025, while news highlights temporary mining suspension at Barnat pit but affirms long-term growth projects.
Outlook remains positive with a $222.40 analyst consensus target, though risks include operational disruptions and gold price volatility. The stock offers value with robust cash flow and 67.74% buy ratings, but investors should monitor execution of expansion plans amid bearish technical indicators.
ClearPoint Neuro (CLPT) trades at $18.00, down 3.85% with a bullish technical signal from moving averages. The company shows strong revenue growth with 25% organic device growth in Q1 2026 but continues to report significant losses, with a net income margin of -71.57%. Recent FDA clearance for the Velocity Alpha surgical drill and partnership expansion in South Korea highlight ongoing business development. Analyst sentiment remains strongly positive with 100% buy ratings, though the stock faces execution and regulatory risks.
The outlook remains speculative with high growth potential from gene therapy commercialization offset by persistent losses and cash burn. Investment opportunity lies in successful partner therapy commercialization, but risks include regulatory hurdles and the need for continued financing. The stock's valuation at 12.76x sales reflects growth expectations despite negative profitability metrics.
Trailing returns across standard periods
Latest headlines on both assets
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →